Cerepro 250 mg/ml 4 ml, 3 pcs.

Pharmacological action

Cerepro is a central cholinostimulant containing 40.5% metabolically protected choline (metabolic protection promotes choline release in the brain).

On entering the body it is split by the action of enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine – one of the main mediators of neural excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane.

It provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and increases metabolic processes in the central nervous system, activates reticular formation.

It increases linear velocity of blood flow on the side of traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular disease.

Cerepro improves brain function by acting on pathogenetic factors of involutional psychoorganic syndrome, changes phospholipid composition of neuronal membranes and reduces cholinergic activity.

Dose-dependently stimulates acetylcholine release; participating in the synthesis of phosphahydylcholine (membrane phospholipid), improves synaptic transmission, neuronal membrane plasticity, receptor function.

It has no effect on the reproductive cycle and has no teratogenic and mutagenic action.

Pharmacokinetics

Absorption – 88%), easily penetrates through the blood-brain barrier (when taken orally its concentration in the brain is 45%) of that in plasma.) It is excreted mainly by lungs as carbon dioxide (85%) and also by the kidneys and intestines (15%).

Indications

acute and recovery periods of severe traumatic brain injury and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;
psychoorganic syndrome against the background of degenerative and involutional changes in the brain;
chronic cerebrovascular insufficiency;
cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), including dementia and encephalopathy.
senile pseudomelancholia.

Pharmacological effect

Pharmacological action

Cerepro is a central cholinergic stimulant, which contains 40.5% metabolically protected choline (metabolic protection promotes the release of choline in the brain).

When it enters the body, it is broken down by enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine, one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane.

Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.

Increases the linear speed of blood flow on the side of the traumatic brain injury, helps to normalize the spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral reactions of patients with vascular diseases of the brain.

Cerepro improves brain function by affecting the pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.

Dose-dependently stimulates the release of acetylcholine; participating in the synthesis of phosphagidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, and receptor function.

Does not affect the reproductive cycle and does not have teratogenic or mutagenic effects.

Pharmacokinetics

Absorption – 88%), easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45%) of that in plasma). It is excreted primarily by the lungs, in the form of carbon dioxide (85%), as well as by the kidneys and intestines (15%).

Special instructions

If nausea occurs after taking the drug, the dose should be reduced.

Cerepro does not affect the speed of psychomotor reactions.

Active ingredient

Choline alphoscerate

Composition

1 ml of solution for intramuscular and intravenous administration contains:

active ingredient:

250 mg glycerylphosphorylcholine hydrate (choline alphoscerate);

excipient:

water for injections.

Contraindications

Hypersensitivity, pregnancy, breastfeeding.

Side Effects

Allergic reactions, nausea (due to dopaminergic activation).

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

Veropharm LLC, Russia